Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study

BACKGROUND: Serous chorioretinopathy has been associated with MEK inhibitors, including cobimetinib. We describe the clinical features of serous retinopathy observed with cobimetinib in patients with BRAF (V600)-mutated melanoma treated in the Phase III coBRIM study. METHODS: In the coBRIM study, 49...

Descripción completa

Detalles Bibliográficos
Autores principales: de la Cruz-Merino, Luis, Di Guardo, Lorenza, Grob, Jean-Jacques, Venosa, Alfredo, Larkin, James, McArthur, Grant A., Ribas, Antoni, Ascierto, Paolo A., Evans, Jeffrey T. R., Gomez-Escobar, Antonio, Barteselli, Giulio, Eng, Susan, Hsu, Jessie J., Uyei, Anne, Dréno, Brigitte
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5483259/
https://www.ncbi.nlm.nih.gov/pubmed/28646893
http://dx.doi.org/10.1186/s12967-017-1246-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5483259/
https://www.ncbi.nlm.nih.gov/pubmed/28646893
http://dx.doi.org/10.1186/s12967-017-1246-0

Ejemplares similares